Summit Therapeutics Inc (NASDAQ:SMMT) price on current trading day, rose 9.56% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.23.
A look at the stock’s price movement, the close in the last trading session was $16.64, moving within a range at $15.78 and $18.9. The beta value (5-Year monthly) was -0.46. Turning to its 52-week performance, $33.89 and $2.10 were the 52-week high and 52-week low respectively. Overall, SMMT moved -1.46% over the past month.
Summit Therapeutics Inc’s market cap currently stands at around $13.45 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-23.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SMMT is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend SMMT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SMMT’s current price about -6.03% and -8.04% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.80, while 7-day volatility ratio is 13.54% and 8.32% in the 30-day chart. Further, Summit Therapeutics Inc (SMMT) has a beta value of -0.62, and an average true range (ATR) of 1.77. Analysts have given the company’s stock an average 52-week price target of $33.5, forecast between a low of $32 and high of $35. Looking at the price targets, the low is -75.53% off current price level while to achieve the yearly target high, price needs to move -91.99%. Nonetheless, investors will most likely welcome a -83.76% jump to $33.5 which is the analysts’ median price.
If we refocus on Summit Therapeutics Inc (NASDAQ:SMMT), historical trading data shows that trading volumes averaged 3.06 over the past 10 days and 2.57 million over the past 3 months. The company’s latest data on shares outstanding shows there are 737.63 million shares.
The 84.39% of Summit Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 12.61% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 21.22 million on 2025-03-14, giving us a short ratio of 7.34. The data shows that as of 2025-03-14 short interest in Summit Therapeutics Inc (SMMT) stood at 1782.9999999999998 of shares outstanding, with shares short falling to 21.45 million registered in 2025-02-14. Current price change has pushed the stock 2.16% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SMMT stock continues to rise going into the next quarter.
